Background 

For people with muscle-invasive bladder cancer, chemotherapy using a drug called cisplatin before surgery is a common and recommended treatment. This is known as neoadjuvant chemotherapy (NAC). However, this treatment only helps about one in four patients, and doctors currently have no reliable way to predict who will benefit. The same chemotherapy is given to everyone, even though bladder cancers can behave very differently from person to person. Patients whose cancer does not respond to chemotherapy often have poor outcomes, even after surgery to remove the bladder. 

What the Study Proposes to Address 

Researchers know that differences in certain genes—especially those involved in repairing damaged DNA—may explain why some tumors resist chemotherapy. Earlier work from a national study called The Cancer Genome Atlas (TCGA) has already shown that bladder cancer can be divided into subtypes based on which genes are active. 

These differences could help predict which patients will respond to treatment. This study builds on those findings by focusing on both genes and proteins in patients who are about to receive cisplatin-based chemotherapy. Using advanced tools like mass spectrometry and computer-based analysis, researchers will study how genetic changes affect the proteins that actually control cancer growth and response to treatment. They will test new drugs in special pre-clinical systems—including one that grows tumors in chicken eggs and another that uses mice implanted with human tumors—to find therapies that might work better for specific patients. 

Why This Research is Important 

This project aims to move away from the “one size fits all” approach to treating bladder cancer. By understanding why some patients respond to chemotherapy and others do not, doctors can better match each person with the treatment most likely to work for them. The results could help create a more personalized approach to bladder cancer care—often called precision medicine—where the right drug is chosen for the right patient at the right time. In the future, this research could lead to better survival rates and fewer unnecessary treatments for people facing this aggressive form of bladder cancer.